Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations" for multiple sclerosis and related disorders
- PMID: 32036262
- DOI: 10.1016/j.msard.2020.101975
Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations" for multiple sclerosis and related disorders
Conflict of interest statement
Declaration of Competing Interest Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Roche and Teva Harald Hegen: has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens and Teva, and received honoraria for consulting Teva Thomas Berger: has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Celgene, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi Aventis, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva.
Comment on
-
To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.Mult Scler Relat Disord. 2020 Apr;39:101908. doi: 10.1016/j.msard.2019.101908. Epub 2019 Dec 23. Mult Scler Relat Disord. 2020. PMID: 31896060
-
To treat or not to treat study: Comparative group inclusion considerations.Mult Scler Relat Disord. 2020 May;40:101976. doi: 10.1016/j.msard.2020.101976. Epub 2020 Jan 30. Mult Scler Relat Disord. 2020. PMID: 32032842 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources